Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 3/2012

01-03-2012 | Original Research

Uric Acid is an Important Predictor for Hypertensive Early Atherosclerosis

Authors: Ruya Mutluay, Serpil Muge Deger, Eylem Bahadir, Alim Ozgur Durmaz, Riza Çitil, Sukru Sindel

Published in: Advances in Therapy | Issue 3/2012

Login to get access
Metadata
Title
Uric Acid is an Important Predictor for Hypertensive Early Atherosclerosis
Authors
Ruya Mutluay
Serpil Muge Deger
Eylem Bahadir
Alim Ozgur Durmaz
Riza Çitil
Sukru Sindel
Publication date
01-03-2012
Publisher
Springer Healthcare Communications
Published in
Advances in Therapy / Issue 3/2012
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-012-0006-z

Other articles of this Issue 3/2012

Advances in Therapy 3/2012 Go to the issue

Review

Apixaban: an Oral Direct Factor-Xa Inhibitor

Original Research

Contribution of Endermology to Improving Indurations and Panniculitis/Lipoatrophy at Glatiramer Acetate Injection Site

Review

Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

Review

Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma

Original Research

Exploring Channeling Optimized Radiofrequency Energy: a Review of Radiofrequency History and Applications in Esthetic Fields

Original Research

Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits